|
|
Volumn 11, Issue 10, 2010, Pages 912-913
|
|
Kinase inhibitors for refractory thyroid cancers
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
CISPLATIN;
DOXORUBICIN;
FLUORODEOXYGLUCOSE F 18;
LEVOTHYROXINE;
MOTESANIB;
PAZOPANIB;
PHOSPHOTRANSFERASE INHIBITOR;
PLACEBO;
RADIOACTIVE IODINE;
SORAFENIB;
SUNITINIB;
TAXANE DERIVATIVE;
VANDETANIB;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
PYRIMIDINE DERIVATIVE;
SULFONAMIDE;
ARTIFICIAL EMBOLISM;
BONE METASTASIS;
CANCER RADIOTHERAPY;
CANCER REGRESSION;
CANCER SURVIVAL;
CLINICAL TRIAL;
HUMAN;
LUNG METASTASIS;
NOTE;
OFF LABEL DRUG USE;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
RADIOFREQUENCY;
THYROID CANCER;
THYROID FOLLICULAR CARCINOMA;
THYROID PAPILLARY CARCINOMA;
THYROID SURGERY;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
CELL DIFFERENTIATION;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
MORTALITY;
MULTICENTER STUDY (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
SECONDARY;
THYROID NEOPLASMS;
TIME;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CELL DIFFERENTIATION;
CLINICAL TRIALS, PHASE II AS TOPIC;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
HUMANS;
MULTICENTER STUDIES AS TOPIC;
PROTEIN KINASE INHIBITORS;
PYRIMIDINES;
SULFONAMIDES;
THYROID NEOPLASMS;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 77957336589
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(10)70226-6 Document Type: Note |
|
Times cited : (10)
|
|
References (5)
|
